Anthem Biosciences Approves Final Dividend, Recommends Key Directorships, and Announces FY26 Results

Anthem Biosciences Approves Final Dividend, Recommends Key Directorships, and Announces FY26 Results​

Anthem Biosciences Limited announced the outcomes of its Board Meeting held on May 19, 2026. The Board considered and approved the audited financial results for the quarter and year ended March 31, 2026, and recommended several corporate actions, including a final dividend and the allotment of shares under its employee stock option plan.

Financial Performance and Dividend Recommendation​

The Board of Directors approved the Audited Standalone and Consolidated Financial Results, prepared as per Indian Accounting Standards (Ind-AS), along with the accompanying Auditor's reports for the quarter and year ended March 31, 2026.

The financial results show the following summarized figures for the Standalone entity (in ₹ Millions):


For the consolidated results, the total assets stood at 34,292.90 million as at March 31, 2026, compared to 28,075.83 million the previous year.

The Board recommended a final dividend of INR 2.00 per equity share of face value of INR 2.00 each for the Financial Year ended March 31, 2026. This dividend remains subject to the Shareholders' approval at the Annual General Meeting. The record date for the dividend payment is set for Friday, June 26, 2026.

Capital Structure and Equity Allotment​

The Board approved the allotment of 14,81,250 Equity Shares of face value of INR 2.00 each to eligible employees of the Company, pursuant to the exercise of Options vested under the Anthem Employee Stock Option Plan 2024.

This allotment increased the paid-up equity share capital of Anthem Biosciences Limited:

Governance and Director Updates​

The Board meeting also focused on the company's governance structure, making key recommendations for the Annual General Meeting.

Director Appointments:
1. Mr. Ravikant Uppal: The Board recommended the continuation of Mr. Ravikant Uppal as a Non-Executive Independent Director. His tenure is subject to Shareholder approval at the ensuing Annual General Meeting.
2. Mr. Ravindra Chandrappa: The Board approved and recommended the re-appointment of Mr. Ravindra Chandrappa as a Whole Time Director, following his retirement by rotation.

Auditors and Meetings:
The Board approved the re-appointment of M/s. BPU & Co., Chartered Accountants, as the Internal Auditors for the Financial Year 2026-2027. Additionally, the Board approved convening the 20th Annual General Meeting (AGM) on Wednesday, July 22, 2026.

Financial Highlights Summary​

The company's capital structure and asset base showed growth in the financial year.


Furthermore, the Cash and Cash Equivalents (ending) for the period were reported at 2,698.53 million, compared to 1,662.54 million at the beginning of the year.

ANTHEM Stock Price Movement​

On Tuesday, Anthem Biosciences Limited shares slipped by 1.12% to settle at ₹787.35. The equity recorded 293,810 shares in turnover, indicating notable selling pressure throughout the session.